Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Importance Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. Design, Setting, and Participants The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. Main Outcomes and Measures Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. Exposures At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined. Results The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). Conclusions and Relevance In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding. Trial Registration ClinicalTrials.gov Identifier: NCT00391872.

[1]  Søren B. Padkjær,et al.  GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand , 2017, Nature Medicine.

[2]  P. Emmerson,et al.  The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL , 2017, Nature Medicine.

[3]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.

[4]  C. Held,et al.  Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. , 2017, Journal of the American College of Cardiology.

[5]  S. Yusuf,et al.  Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial , 2017, American heart journal.

[6]  C. Cannon,et al.  Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding , 2017, Journal of the American Heart Association.

[7]  C. Cannon,et al.  Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. , 2017, Clinical chemistry.

[8]  C. Held,et al.  Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. , 2017, Clinical chemistry.

[9]  J. Alfredsson,et al.  Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study , 2017, European heart journal. Quality of care & clinical outcomes.

[10]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[11]  E. Hagström,et al.  Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. , 2016, European heart journal.

[12]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[13]  M. Link,et al.  B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. , 2014, Heart rhythm.

[14]  C. Held,et al.  Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes , 2014, Heart.

[15]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[16]  L. Lind,et al.  Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.

[17]  A. Zarbock,et al.  GDF‐15 prevents platelet integrin activation and thrombus formation , 2013, Journal of thrombosis and haemostasis : JTH.

[18]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[19]  U. Haberkorn,et al.  Growth Differentiation Factor‐15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin‐6–Dependent Inflammatory Response to Vascular Injury , 2012, Journal of the American Heart Association.

[20]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[21]  L. Lind,et al.  Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.

[22]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[23]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[24]  H. Oswald,et al.  Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction. , 2007, The American journal of cardiology.

[25]  P. Poole‐Wilson,et al.  Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.

[26]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[27]  R. Califf,et al.  Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.

[28]  K. Bibbins-Domingo,et al.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.

[29]  R. Califf,et al.  Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. , 2006, Journal of the American College of Cardiology.

[30]  L. Wallentin,et al.  Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction , 2005, Heart.

[31]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[32]  K. Unsicker,et al.  Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions , 2004, Cell and Tissue Research.

[33]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[34]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.